Fast Five Quiz: Pulmonary Arterial Hypertension Treatment

Vikramjit Khangoora, MD


June 02, 2022

The only therapy that has demonstrated a direct survival benefit in patients with PAH is intravenous epoprostenol, a prostanoid vasodilator. Epoprostenol improves exercise capacity, hemodynamics, and survival and is effective in PAH related to connective tissue disorders, congenital heart disease, and drug-induced pulmonary hypertension. It is recommended that all patients in intermediate- to high-risk groups be initiated on combination therapy, including a parenteral pulmonary vasodilator for high-risk patients.

Learn more about pulmonary arterial hypertension.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.